QualityStocks would like to highlight RegeneRx (OTCBB: RGRX), focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tβ4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in Phase 2 clinical development and has an extensive worldwide patent portfolio covering its products. RegeneRx is a clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.
In the company’s news last week,
RegeneRx Biopharmaceuticals stated that data regarding their novel, therapeutic peptide, Thymosin beta 4 (TB4), was published in the May 2012 edition of the Journal of Neurosurgery, 116:1081—1092. The data shows that TB4 “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI).”
The aims of the study were to test if TB4 treatment decreases brain damage and improves functional recovery in rats if the treatment is initiated 6 hours after traumatic brain injury. The research team states, “Compared with saline administration, TB4 treatment initiated 6 hours postinjury significantly improved sensorimotor functional recovery and spatial learning, reduced cortical lesion volume and hippocampal cell loss, and enhanced cell proliferation and neurogenesis in the injured hippocampus. Thymosin B4 treatment initiated 6 hours postinjury provides both neuroprotection and neurorestoration after TBI, indicating that TB4 has promising therapeutic potential in patients with TBI.”
“These results are extremely encouraging and are consistent with results of TB4 administration in other Central nervous system injuries, as well as in cardiovascular injury models. Moreover, the reduction of brain damage, improved motor function, and regeneration of injured brain tissue, when TB4 is administered 6 hours after TBI, suggest that it could potentially be useful for the treatment of brain traumas seen in the military, the workplace and in contact sports,” stated Dr. Allan Goldstein, Professor and Chairman Emeritus, Department of Biochemistry and Molecular Biology, The George Washington University School of Medicine, Washington, D.C. Dr. Goldstein is also chairman of and chief scientific advisor to RegeneRx.
The research team consisted of Xiong Y, Zhang Y, Mahmood A, Meng Y, Zhang ZG, Morris DC, and Chopp MJ. The researchers are from the Departments of Neurosurgery, Neurology, and Emergency Medicine at the Henry Ford Hospital System (HFHS), in Detroit, Michigan, and Department of Physics, Oakland University, in Rochester, Michigan, in accordance with a material transfer agreement between the RegeneRx Biopharmaceuticals, Inc. and Henry Ford Hospital.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.